© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 9, 661-668,
May 7, 2003
© 2003 Oxford University Press
ARTICLE |
Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer
Affiliations of authors: D. R. Rhodes (Department of Pathology), M. G. Sanda (Department of Urology), A. M. Chinnaiyan (Departments of Pathology and Urology), University of Michigan School of Medicine, Ann Arbor, MI; A. P. Otte, Department of Biochemistry, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands; M. A. Rubin, Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
Correspondence to: Mark A. Rubin, M.D., Department of Pathology, Brigham & Women’s Hospital, 75 Francis St., Boston, MA 02115 (e-mail: marubin{at}partners.org).
Background: Molecular signatures in cancer tissue may be useful for diagnosis and are associated with survival. We used results from high-density tissue microarrays (TMAs) to define combinations of candidate biomarkers associated with the rate of prostate cancer progression after radical prostatectomy that could identify patients at high risk for recurrence. Methods: Fourteen candidate biomarkers for prostate cancer for which antibodies are available included hepsin, pim-1 kinase, E-cadherin (ECAD; cell adhesion molecule), 
-methylacyl-coenzyme A racemase, and EZH2 (enhancer of zeste homolog 2, a transcriptional repressor). TMAs containing more than 2000 tumor samples from 259 patients who underwent radical prostatectomy for localized prostate cancer were studied with these antibodies. Immunohistochemistry results were evaluated in conjunction with clinical parameters associated with prostate cancer progression, including tumor stage, Gleason score, and prostate-specific antigen (PSA) level. Recurrence was defined as a postsurgery PSA level of more than 0.2 ng/mL. All statistical tests were two-sided. Results: Moderate or strong expression of EZH2 coupled with at most moderate expression of ECAD (i.e., a positive EZH2:ECAD status) was the biomarker combination that was most strongly associated with the recurrence of prostate cancer. EZH2:ECAD status was statistically significantly associated with prostate cancer recurrence in a training set of 103 patients (relative risk [RR] = 2.52, 95% confidence interval [CI] = 1.09 to 5.81; P = .021), in a validation set of 80 patients (RR = 3.72, 95% CI = 1.27 to 10.91; P = .009), and in the combined set of 183 patients (RR = 2.96, 95% CI = 1.56 to 5.61; P<.001). EZH2:ECAD status was statistically significantly associated with disease recurrence even after adjusting for clinical parameters, such as tumor stage, Gleason score, and PSA level (hazard ratio = 3.19, 95% CI = 1.50 to 6.77; P = .003). Conclusion: EZH2:ECAD status was statistically significantly associated with prostate cancer recurrence after radical prostatectomy and may be useful in defining a cohort of high-risk patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. D.W. Karanikolas, M. L. Figueiredo, and L. Wu Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line Mol. Cancer Res., September 1, 2009; 7(9): 1456 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. BICKERS and C. AUKIM-HASTIE New Molecular Biomarkers for the Prognosis and Management of Prostate Cancer - The Post PSA Era Anticancer Res, August 1, 2009; 29(8): 3289 - 3298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Mello, E. F. Abrantes, C. H. Torres, A. Machado-Lima, R. d. S. Fonseca, D. M. Carraro, R. R. Brentani, L. F. L. Reis, and H. Brentani No-match ORESTES explored as tumor markers Nucleic Acids Res., May 1, 2009; 37(8): 2607 - 2617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gopalan, M. A. Leversha, J. M. Satagopan, Q. Zhou, H. A. Al-Ahmadie, S. W. Fine, J. A. Eastham, P. T. Scardino, H. I. Scher, S. K. Tickoo, et al. TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy Cancer Res., February 15, 2009; 69(4): 1400 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Norris, M. Gentry, D. M. Peehl, R. D'Agostino Jr., and K. D. Scarpinato The Elevated Expression of a Mismatch Repair Protein Is a Predictor for Biochemical Recurrence After Radical Prostatectomy Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 57 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sardana, B. Dowell, and E. P. Diamandis Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer Clin. Chem., December 1, 2008; 54(12): 1951 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lin, A. G. Utleg, K. Gravdal, J. T. White, O. J. Halvorsen, W. Lu, L. D. True, R. Vessella, P. H. Lange, P. S. Nelson, et al. WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence Clin. Cancer Res., March 1, 2008; 14(5): 1397 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Banyard, L. Bao, M. D. Hofer, D. Zurakowski, K. A. Spivey, A. S. Feldman, L. M. Hutchinson, R. Kuefer, M. A. Rubin, and B. R. Zetter Collagen XXIII Expression Is Associated with Prostate Cancer Recurrence and Distant Metastases Clin. Cancer Res., May 1, 2007; 13(9): 2634 - 2642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tan, X. Yang, L. Zhuang, X. Jiang, W. Chen, P. L. Lee, R.K. M. Karuturi, P. B. O. Tan, E. T. Liu, and Q. Yu Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells Genes & Dev., May 1, 2007; 21(9): 1050 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. W. Howard, M.-T. Ling, C. W. Chua, H. W. Cheung, X. Wang, and Y. C. Wong Garlic-Derived S-allylmercaptocysteine Is a Novel In vivo Antimetastatic Agent for Androgen-Independent Prostate Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1847 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Stephenson, P. T. Scardino, J. A. Eastham, F. J. Bianco Jr, Z. A. Dotan, C. J. DiBlasio, A. Reuther, E. A. Klein, and M. W. Kattan Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy J. Clin. Oncol., October 1, 2005; 23(28): 7005 - 7012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chen, S.-w. Tu, and J.-T. Hsieh Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer J. Biol. Chem., June 10, 2005; 280(23): 22437 - 22444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rubin, T. A. Bismar, O. Andren, L. Mucci, R. Kim, R. Shen, D. Ghosh, J. T. Wei, A. M. Chinnaiyan, H.-O. Adami, et al. Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1424 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Etzioni, S. Hawley, D. Billheimer, L. D. True, and B. Knudsen Analyzing Patterns of Staining in Immunohistochemical Studies: Application to a Study of Prostate Cancer Recurrence Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1040 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jacquemier, C. Ginestier, J. Rougemont, V.-J. Bardou, E. Charafe-Jauffret, J. Geneix, J. Adelaide, A. Koki, G. Houvenaeghel, J. Hassoun, et al. Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis Cancer Res., February 1, 2005; 65(3): 767 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Mell, J. J. Meyer, M. Tretiakova, A. Khramtsov, C. Gong, S. D. Yamada, A. G. Montag, and A. J. Mundt Prognostic Significance of E-Cadherin Protein Expression in Pathological Stage I-III Endometrial Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5546 - 5553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Pepe, H. Janes, G. Longton, W. Leisenring, and P. Newcomb Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker Am. J. Epidemiol., May 1, 2004; 159(9): 882 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Hofer, R. Kuefer, S. Varambally, H. Li, J. Ma, G. I. Shapiro, J. E. Gschwend, R. E. Hautmann, M. G. Sanda, K. Giehl, et al. The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression Cancer Res., February 1, 2004; 64(3): 825 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kuefer, M. D. Hofer, J. E. Gschwend, K. J. Pienta, M. G. Sanda, A. M. Chinnaiyan, M. A. Rubin, and M. L. Day The Role of an 80 kDa Fragment of E-cadherin in the Metastatic Progression of Prostate Cancer Clin. Cancer Res., December 15, 2003; 9(17): 6447 - 6452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Kattan Judging New Markers by Their Ability to Improve Predictive Accuracy J Natl Cancer Inst, May 7, 2003; 95(9): 634 - 635. [Full Text] [PDF]
|
|